N@N

CNS Response to Receive Fourth U.S. Patent

^{Published on 2010-06-30 09:30:35 - Market Wire}
 

ALISO VIEJO, CA--(Marketwire - June 30, 2010) - CNS Response, Inc. (OTCBB: [ CNSO ]) today announced that the U.S. Patent and Trademark Office has allowed patent number 77,54,190, Method for Determining Drug Effects Using Quantitative EEG, which extends application of the Company's Referenced-EEG^® technology platform to improve the performance and efficacy of clinical trials conducted by pharmaceutical companies. The patent will be published July 13, 2010.

"As the costs of discovering and testing new drugs have soared, particularly those in the central nervous system (CNS) class, Referenced-EEG presents new opportunities for the pharmaceutical industry," said CNS Response CEO George Carpenter. "Our patented methodology can assist pharmaceutical companies in drug discovery, program evaluation, and clinical trial design."

The contribution of Referenced-EEG has been successfully demonstrated in numerous clinical studies, including the multi-site Depression Efficacy Study completed in 2009. CNS Response submitted a 510(k) for review by the FDA in April 2010.

About CNS Response
Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.

Referenced-EEG was developed by physicians to provide objective, statistical data on patient neurophysiology. In clinical trials, physicians using Referenced-EEG data have consistently achieved superior clinical results compared to physicians using trial and error pharmacotherapy.

To read more about this patented technology, please visit the CNS Response website, [ www.cnsresponse.com ].

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.